Search results
Author(s):
Meril Life Sciences
Added:
3 years ago
The first-generation drug-eluting stents (DES) initially demonstrated good promise in terms of reducing the degree of restenosis. They succeeded in arresting the neo-intimal proliferation, which was the bane of coronary stents.1 Over a period of time, however, the polymeric degradation by-products failed to bring about an essential component of the healing process: endothelialisation. Failure of…
View more
Added:
3 years ago
By Liam O’Neill at TCT 2014.
Delegates at the 26thannual Transcatheter Cardiovascular Therapeutics (TCT) heard first hand about the Chinese BRIGHT trial, the first to compare bivalirudin,unfractionated heparin(UFH) alone, and heparin plus a GP IIb/IIIa inhibitor (tirofiban).
The new analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained superior to…
View more
Author(s):
Corrado Tamburino
,
Davide Capodanno
Added:
3 years ago
Recently, many eminent scientific journals have published long-term follow-up data from both randomised clinical trials (RCTs) and registries of patients treated with percutaneous coronary intervention (PCI) undergoing drug-eluting stent (DES) implantation. In fact, this is the only course of action to address the concerns regarding DES safety that were first raised almost two years ago.1…
View more
Author(s):
Rick Volleberg
,
Stijn van den Oord
,
Robert-Jan van Geuns
Added:
1 year ago
Author(s):
Stéphane G Carlier
Added:
3 years ago
Cordis Corporation recently announced that it has received CE mark approval for the treatment of acute myocardial infarction (AMI) using the CYPHER® SELECT™ PLUS sirolimus-eluting coronary stent. CE marking means conformity to the applicable European Directive, and in the specific context of AMI permits the CYPHER stent to be placed on the market for treatment of AMI in all Member States of the…
View more
Author(s):
Savio D’Souza
,
Giuseppe Ferrante
,
Pawel Tyczynski
,
et al
Added:
3 years ago
Percutaneous coronary intervention (PCI) deploying metallic stents is now a standard and routine procedure for the treatment of flow-limiting coronary stenosis in patients with ischaemic heart disease and is an alternative to surgery. Stents were invented to overcome limitations of balloon angioplasty coronary dissections, acute and subacute elastic recoil, intimal hyperplasia and negative vessel…
View more
Author(s):
Nicolas Foin
,
Eduardo Alegria-Barrero
,
Ryo Torii
,
et al
Added:
3 years ago
Drug-eluting stents (DESs) have contributed to a significant lowering of the incidence of restenosis and target vessel revascularisation (TVR) in bifurcations.1–4 A randomised study of bifurcation lesions using sirolimus-eluting stents revealed restenosis rates of only 4 % in the main branch (MB) and a TVR rate as low as 8.2 % at six-month follow-up,2 a marked improvement over that in historical…
View more
Added:
3 years ago
Source:
http://www.biotronik.com/wps/wcm/connect/int_web/biotronik/newsroom/press_relea…
Drug-Eluting Stent Demonstrates Enhanced Safety and Three-Times Reduced Risk of Stent Thrombosis
One Year Data from Industry-Independent SORT OUT VII Trial Presented at EuroPCR 2015 Reveals Orsiro Is Non-Inferior to Nobori Stent in Large, All-Comers Population
BUELACH, Switzerland, May 26, 2015—BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that…
View more
Author(s):
Nieves Gonzalo
,
Javier Escaned
,
Fernando Alfonso
Added:
3 years ago
Background
Incomplete stent apposition (ISA) is defined as a separation of at least one stent strut from the vessel wall, not related with a side branch. The relevance of this phenomenon derives from intravascular ultrasound (IVUS) studies suggesting a potential relationship between ISA and stent thrombosis. The mechanism by which ISA can contribute to stent thrombosis remains unknown, but it has…
View more
Author(s):
Fumiyuki Otsuka
,
Masataka Nakano
,
Saami K Yazdani
,
et al
Added:
3 years ago
Percutaneous coronary interventions (PCI) involving stenting are the most widely performed procedures for the treatment of symptomatic coronary disease.1 Although first-generation sirolimus-eluting stents (SES; Cypher™, Cordis Corp., Miami Lakes, FL) and paclitaxel-eluting stents (PES; Taxus™, Boston Scientific, Natick, MA) have radically reduced restenosis,2,3 complications of late (LST) and…
View more